| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| D412014-100μg |
100μg |
现货  |
| |
| D412014-1mg |
1mg |
现货 |
| |
| D412014-5mg |
5mg |
现货 |
| |
| D412014-10mg |
10mg |
期货 |
|
| 产品名称 | Daratumumab (anti-CD38), CD38 抗体 |
|---|---|
| 别名 | 达雷木单抗(抗 CD38) |
| 英文别名 | 2.4.99.20 | 2'-phospho-ADP-ribosyl cyclase | 2'-phospho-ADP-ribosyl cyclase/2'-phospho-cyclic-ADP-ribose transferase | 2'-phospho-cyclic-ADP-ribose transferase | ADPRC 1 | ADP-ribosyl cyclase 1 | cADPr hydrolase 1 | Cyclic ADP-ribose hydrolase 1 | EC 3.2. |
| 规格或纯度 | 无载体, 重组, ExactAb™, 低内毒素, 无叠氮钠, 已验证, 无动物源, ≥95%(SDS-PAGE&SEC-HPLC), 见COA |
| 宿主种属 | 人(Human) |
| 特异性 | CD38 |
| 应用 | ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) |
| 种属反应性 | 人(Human),小鼠(Mouse),恒河猴(Rhesus monkey),食蟹猴(Cynomolgus monkey) |
| 偶联 | Unconjugated |
| 作用类型 | 抑制剂 |
| 作用机制 | CD38 抗体 |
| 抗体类型 | Primary antibody |
|---|---|
| 克隆类型 | 重组抗体 |
| Format | Whole IgG |
| 亚型 | Human IgG1 |
| 轻链亚型 | kappa |
| SDS-PAGE | 24.5 kDa (Light Chain) & 50.3 kDa (Heavy Chain), under reducing conditions; 175.9 kDa, under non-reducing conditions. |
| 纯化方法 | Protein A purified |
| 纯度 | >95% |
| 来源 | CHO supernatant |
| 物理外观 | Liquid |
| 储存缓冲液 | Supplied as a 0.22 μm filtered solution in 100mM Pro-Ac, 20mM Arg, pH 5.0 |
| 防腐剂 | No |
| 浓度 | 见COA |
| 储存温度 | -80℃储存,避免反复冻融 |
| 运输条件 | 超低温冰袋运输 |
| 稳定性与储存 | 在 -80℃ 下保存 24 个月。收货后建议分装。避免冷冻/解冻循环。 |
| CAS编号和信息 | 945721-28-8 |
| 分子类型 | 抗体 |
Daratumumab (anti-CD38) (D412014) - Flow Cytometry
Flow Cytometry analysis of Raji cells labelling CD38 (red) with Daratumumab (anti-CD38) (D412014). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.
Daratumumab (anti-CD38) (D412014) - SEC
The purity of Daratumumab (anti-CD38) (D412014) is more than 95% verified by HPLC.
Daratumumab (anti-CD38) (D412014) - ELISA
Immobilized human-CD38-ECD-Nhis at 2 μg/mL can bind Daratumumab (anti-CD38) (D412014) with the EC50 of 30.71 ng/mL.
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
通过匹配包装上的批号来查找并下载产品的 COA，每批产品都进行了严格的验证，您可放心使用！
| 批号(Lot Number) | 证书类型 | 日期 | 货号 |
|---|---|---|---|
 ZJ24F1012695 |
分析证书 | 24-10-23 | D412014 |
| ZJ24F1012694 |
分析证书 | 24-10-23 | D412014 |
| ZJ24F1012693 |
分析证书 | 24-10-23 | D412014 |
| ZJ24F0404209 |
分析证书 | 24-04-08 | D412014 |
| ZJ24F0404210 |
分析证书 | 24-04-08 | D412014 |
| ZJ24F0404211 |
分析证书 | 24-04-08 | D412014 |
¥559.90
¥259.90
¥299.90
¥479.90
¥169.90
¥199.90
¥139.90
¥599.90
¥259.90
| 1. van der Veer MS, de Weers M, van Kessel B, Bakker JM, Wittebol S, Parren PW, Lokhorst HM, Mutis T. (2011) Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab.. Haematologica, 96 (2): (284-90). [PMID:21109694] [10.1021/op500134e] |
| 2. de Weers M, Tai YT, van der Veer MS, Bakker JM, Vink T, Jacobs DC, Oomen LA, Peipp M, Valerius T, Slootstra JW et al.. (2011) Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.. J Immunol, 186 (3): (1840-8). [PMID:21187443] [10.1021/op500134e] |
| 3. van der Veer MS, de Weers M, van Kessel B, Bakker JM, Wittebol S, Parren PW, Lokhorst HM, Mutis T. (2011) The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies.. Blood Cancer J, 1 (10): (e41). [PMID:22829073] [10.1021/op500134e] |
| 4. Sanford M, McCormack PL. (2016) A Three-Drug Combo for Multiple Myeloma.. Cancer Discov, 6 (11): (OF4). [PMID:27630127] [10.1021/op500134e] |
| 5. Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P et al.. (2004) The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).. Genome Res, 14 (10B): (2121-7). [PMID:15489334] [10.1021/op500134e] |
| 6. Jackson DG, Bell JI. (1990) Isolation of a cDNA encoding the human CD38 (T10) molecule, a cell surface glycoprotein with an unusual discontinuous pattern of expression during lymphocyte differentiation.. J Immunol, 144 (7): (2811-5). [PMID:2319135] [10.1021/op500134e] |
| 7. Isabelle Kuhn,Esther Kellenberger,Fatouma Said-Hassane,Pascal Villa,Didier Rognan,Annelise Lobstein,Jacques Haiech,Marcel Hibert,Francis Schuber,Hélène Muller-Steffner. (2010-10-19) Identification by high-throughput screening of inhibitors of Schistosoma mansoni NAD(+) catabolizing enzyme.. Bioorganic & medicinal chemistry, 18 ((22)): (7900-7910). [PMID:20951593] |
| 8. Thomas R Burkard,Melanie Planyavsky,Ines Kaupe,Florian P Breitwieser,Tilmann Bürckstümmer,Keiryn L Bennett,Giulio Superti-Furga,Jacques Colinge. (2011-01-29) Initial characterization of the human central proteome.. BMC systems biology, 5 (17-17). [PMID:21269460] |
| 9. Swarbrick JM, Graeff R, Zhang H, Thomas MP, Hao Q, Potter BV.. (2014) Cyclic adenosine 5'-diphosphate ribose analogs without a "southern" ribose inhibit ADP-ribosyl cyclase-hydrolase CD38.. J Med Chem, 57 (20): (8517-8529). [PMID:25226087] [10.1021/jm501037u] |
| 10. Jacques SA, Kuhn I, Koniev O, Schuber F, Lund FE, Wagner A, Muller-Steffner H, Kellenberger E.. (2015) Discovery of Potent Inhibitors of Schistosoma mansoni NAD⁺ Catabolizing Enzyme.. J Med Chem, 58 (8): (3582-3592). [PMID:25803425] [10.1021/acs.jmedchem.5b00203] |
| 11. Becherer JD, Boros EE, Carpenter TY, Cowan DJ, Deaton DN, Haffner CD, Jeune MR, Kaldor IW, Poole JC, Preugschat F, Rheault TR, Schulte CA, Shearer BG, Shearer TW, Shewchuk LM, Smalley TL, Stewart EL, Stuart JD, Ulrich JC.. (2015) Discovery of 4-Amino-8-quinoline Carboxamides as Novel, Submicromolar Inhibitors of NAD-Hydrolyzing Enzyme CD38.. J Med Chem, 58 (17): (7021-7056). [PMID:26267483] [10.1021/acs.jmedchem.5b00992] |
| 12. Deaton DN, Haffner CD, Henke BR, Jeune MR, Shearer BG, Stewart EL, Stuart JD, Ulrich JC.. (2018) 2,4-Diamino-8-quinazoline carboxamides as novel, potent inhibitors of the NAD hydrolyzing enzyme CD38: Exploration of the 2-position structure-activity relationships.. Bioorg Med Chem, 26 (8): (2107-2150). [PMID:29576271] [10.1016/j.bmc.2018.03.021] |
| 13. States, D J DJ, Walseth, T F TF and Lee, H C HC.. (1992) Similarities in amino acid sequences of Aplysia ADP-ribosyl cyclase and human lymphocyte antigen CD38.. Trends in biochemical sciences, [PMID:1471258] |
| 14. Tohgo, A A and 8 more authors.. (1994) Essential cysteine residues for cyclic ADP-ribose synthesis and hydrolysis by CD38.. The Journal of biological chemistry, (18): [PMID:7961800] |
| 15. Takasawa, S S and 7 more authors.. (1993) Synthesis and hydrolysis of cyclic ADP-ribose by human leukocyte antigen CD38 and inhibition of the hydrolysis by ATP.. The Journal of biological chemistry, (15): [PMID:8253715] |
| 16. Nata, K K and 9 more authors.. (1997) Human gene encoding CD38 (ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase): organization, nucleotide sequence and alternative splicing.. Gene, (28): [PMID:9074508] |
| 17. Yagui, K K and 13 more authors.. (1998) A missense mutation in the CD38 gene, a novel factor for insulin secretion: association with Type II diabetes mellitus in Japanese subjects and evidence of abnormal function when expressed in vitro.. Diabetologia, [PMID:9754820] |
| 18. Hillman, R Tyler RT, Green, Richard E RE and Brenner, Steven E SE.. (2004) An unappreciated role for RNA surveillance.. Genome biology, [PMID:14759258] |
| 19. Liu, Qun Q and 5 more authors.. (2005) Crystal structure of human CD38 extracellular domain.. Structure (London, England : 1993), [PMID:16154090] |
| 20. Wollscheid, Bernd B and 7 more authors.. (2009) Mass-spectrometric identification and relative quantification of N-linked cell surface glycoproteins.. Nature biotechnology, [PMID:19349973] |
首页
400-620-6333
